导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.69% | 1543/4773 |
| 近一周 | -1.66% | 629/5462 |
| 近一月 | -2.87% | 1442/5421 |
| 近一季 | -2.47% | 1247/5209 |
| 近半年 | -2.07% | 1766/4920 |
| 近一年 | 5.34% | 1612/4366 |
| 近两年 | 39.67% | 1909/2954 |
| 近三年 | 22.34% | 1390/2253 |
| 成立以来 | 43.04% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.91% 2554/4961 |
11.42% 2333/5312 |
- - |
- - |
| 2025 | 12.06% 2708/4813 |
-2.92% 3008/3635 |
1.80% 2125/4076 |
13.48% 2989/4524 |
-0.09% 2352/4813 |
| 2024 | 15.12% 965/3463 |
4.93% 416/2808 |
-0.21% 704/3014 |
13.05% 2256/3129 |
-2.74% 2171/3463 |
| 2023 | -7.37% 913/2656 |
6.02% 735/2280 |
-3.72% 876/2385 |
-2.85% 767/2515 |
-6.59% 1838/2655 |
| 2022 | -15.88% 434/2207 |
-12.22% 592/1919 |
6.56% 665/2016 |
-11.19% 506/2113 |
1.26% 1324/2208 |
| 2021 | 3.34% 616/1822 |
-2.34% 625/1255 |
3.69% 959/1330 |
-0.36% 491/1466 |
2.41% 599/1822 |
| 2020 | 26.73% 596/1250 |
-9.40% 673/1028 |
12.84% 664/1067 |
10.50% 544/1164 |
12.17% 495/1184 |
| 2019 | 32.16% 451/1092 |
25.50% 461/754 |
-1.95% 339/804 |
0.47% 514/850 |
6.90% 524/918 |
| 2018 | -25.23% 343/834 |
- - |
- - |
- - |
-12.63% 465/691 |
| 2017 | 14.74% 252/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.30% 355/605 |
- - |
- - |
- - |
- - |
| 2015 | 7.25% 178/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证国有企业改革指数(LOF)A VS. 长安沪深300非周期A(740101) |